Résumé
La cholécystokinine (CCK) est présente dans le cerveau et la moelle épinière où elle agit comme neuromédiateur en activant deux types de récepteurs A et B, ce dernier étant prédominant dans le système nerveux central. Différentes études électrophysiologiques et comportementales plaident en faveur de l'existence d'une interaction entre les systèmes CCK-ergique et opioïde endogènes dans le contrôle de la nociception. Le système CCK-ergique a ainsi été qualifié de système anti-opioïdergique. Expérimentalement, l'administration d'un antagoniste CCK-B potentialise l'effet antinociceptif de la morphine. L'ensemble des données actuelles laisse entrevoir la possibilité d'utiliser des antagonistes CCK-B spécifiques et sélectifs comme analgésiques de complément à la morphine dans le traitement des douleurs postopératories ou chroniques sévères.
Summary
Cholecystokinin (CCK) is located in the brain and the spinal cord. CCK acts as a neuromediator and produces various biological effects that are mediated by two receptors: CCK-A and CCK-B, the predominant form found in the central nervous system. Electrophysiological and behavioural studies suggest the existence of regulatory mechanism between CCK and opioid systems in the control of pain. Thus, it has been proposed that CCK could act as an endogenous opiate and play a role in the development of morphine tolerance. In contrast, administration of a CCK-B receptor antagonist may enhance the antinociceptive effect of morphine. Experimental and clinical studies indicate the possibility for the therapeutic use of selective and specific CCK-B receptor antagonists as co-analgesics with morphine in postoperative period or in patient with intractable pain.
Bibliographie
Baber N.S.: The role of CCK, caerulein, and CCK antagonist in nociception.Pain 39, 307–328, 1989.
Durieux C.: Cholécystokinines et Gastrine.In:Neuropeptides et Neuromédiateurs. Coordinateur J. Epelbaum, Sandoz Ed., Paris, 1992.
Docray G.J.: Immunochemical evidence of CCK-like peptides in brain.Nature 264, 568–570, 1976.
Kinze S.: Pharmacological characterization of CCKB receptors in human brain: no evidence for receptor heterogeneity.Neurescience Letter 217, 45–48, 1996.
Lignon M.F.: CCK increases intracellular calcium concentration in the human Jurkat T Lymphocyte cell line.Eur. J. Pharmacol. 245, 241–246, 1993.
Wang J.F.: Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopiold effect of CCK-8.Peptides 13, 947–951, 1992.
Yamamoto T.: The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat.Anesth. Analg. 83, 107–113, 1996.
Dourish G.T.: The selective CCKB receptor antagonist, L365.260 enhances morphine analgesia and prevents morphine tolerance in the rat.Eur. J. Pharmacol 234, 147–154, 1993.
Noble F.: Modulation of opioid antinoception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain.Br. J. Pharmacol. 109, 1064–1070, 1993.
Paris P.L.: Evidence for the neuropeptide CCK as an antagonist of opiate analgesia.Science 219, 1449–1451, 1983.
Stanfa L.: CCK as a factor in the enhanced potency of spinal morphine following carageenan inflammation.Br. J. Pharmacol. 108, 967–973, 1993.
Stanfa L.: CCK and morphine analgesia: variation on a theme.Trends Pharmacol. Sci. 88, 65–66, 1994.
Xu T.: CCK-8 reverses the kappa-opioid-receptor-mediated depression of calcium current in rat dorsal root ganglion neurons.Brain Res. 730, 207–211, 1996.
Noble F.: Role of endogenous CCK in the facilitation of mu-mediated antinociception by delta opioid agonists.J. Pharmacol. Exp. Ther. 271, 1127–1134, 1994.
Bnoliel J.J.: Mu and delta receptors mediate opposite modulations by morphine of the spinal release of CCK-like material.Brain Res. 653, 81–91, 1994.
Migaud M.: Effects of CCK-8 and BC264, a potent and selective CCKB agonist on asparate and glutamate release from rat hippocampal slices.Neuropharmacol. 33, 737–743, 1994.
Pu S.F.: Cholecystokinine octapeptide antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor.Brain Res. 657, 159–164, 1994.
Zhou Y.: Accelerated expression of CCK gene in the brain of rats rendered tolerant to morphine.Neuroreport 3, 1121–1123, 1992.
Xu X.J.: The CCKB antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats.Neuroreport 5, 718–720, 1994.
Pu S.F.: CCK gene expression in rat amygdaloid neurons: normal distribution and effect of morphine tolerance.Brain Res. Mol. 21, 183–189, 1994.
Benedetti F.: The opposite, effects of the opiate antagonist naloxone and the CCK antagonist proglumide on placebo analgesia.Pain 64, 535–543, 1996.
Lavigne G. Proglumide potentiates morphine analgesia for acute postchirurgical pain.Clin. Pharmacol. Ther. 45, 666–673, 1989.
Author information
Authors and Affiliations
About this article
Cite this article
Mann, C. Les antagonistes de la cholécystokinine: futurs antalgiques?. Doul. et Analg. 10, 127–130 (1997). https://doi.org/10.1007/BF03003146
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03003146